Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression

Psychiatry Research

Volumn 230, Issue 2, 2015, Pages 682-688

  Romeo, Bruno ^a   Choucha, Walid ^a   Fossati, Philippe ^a,b   Rotge, Jean Yves ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Depression; Glutamate; Ketamine; Meta analysis; Mood disorder; Unipolar disorder

Indexed keywords

ANTIDEPRESSANT AGENT; KETAMINE;

BIPOLAR DISORDER; CLINICAL TRIAL (TOPIC); DEPRESSIVE DISORDER; DOUBLE BLIND PROCEDURE; HUMAN; META ANALYSIS; PROCEDURES; PSYCHOLOGY; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; HUMANS; KETAMINE; TREATMENT OUTCOME;

EID: 84947062513     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.10.032     Document Type: Article

References (30)

1. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000, 47:351-354.
2. Caddy C., Giaroli G., White T.P., Shergill S.S., Tracy D.K. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther. Adv. Psychopharmacol. 2014, 4:75-99.
3. Chandley M.J., Szebeni A., Szebeni K., Crawford J.D., Stockmeier C.A., Turecki G., Kostrzewa R.M., Ordway G.A. Elevated gene expression of glutamate receptors in noradrenergic neurons from the locus coeruleus on major depression. Int. J. Neuropsychopharmacol. 2014, 17:1569-1578.
4. Chilukuri H., Reddy N.P., Pathapati R.M., Manu A.N., Jollu S., Shaik A.B. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J. Psychol. Med. 2014, 36:71-76.
5. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Academic Press, New York. second ed.
6. Collins P.Y., Patel V., Joestl S.S., March D., Insel T.R., Daar A.S., Scientific Advisory Board and the Executive Committee of the Grand Challenges on Global Mental Health, Anderson W., Dhansay M.A., Phillips A., Shurin S., Walport M., Ewart W., Savill S.J., Bordin I.A., Costello E.J., Durkin M., Fairburn C., Glass R.I., Hall W., Huang Y., Hyman S.E., Jamison K., Kaaya S., Kapur S., Kleinman A., Ogunniyi A., Otero-Ojeda A., Poo M.M., Ravindranath V., Sahakian B.J., Saxena S., Singer P.A., Stein D.J. Grand challenges in global mental health. Nature 2011, 475:27-30.
7. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
8. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., Kammerer W.A., Quezado Z., Luckenbaugh D.A., Salvadore G., Machado-Vieira R., Manji H.K., Zarate C.A. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 2010, 67:793-802.
9. Duman R.S. Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections. Depression Anxiety 2014, 31:291-296.
10. Dutta A., McKie S., Deakin J.F. Ketamine and other potential glutamate antidepressants. Psychiatry Res. 2015, 225:1-13.
11. Fond G., Loundou A., Rabu C., Macgregor A., Lançon C., Brittner M., Micoulaud-Franchi J.A., Richieri R., Courtet P., Abbar M., Roger M., Leboyer M., Boyer L. Ketamine administration in depressive disorders: a systematic review and meta-analysis. psychopharmacol. (Berl) 2014, 231:3663-3676.
12. Ghasemi M., Phillips C., Trillo L., De Miquel Z., Das D., Salehi A. The role of NMDA receptors in the pathophysiology and treatment of mood disorders. Neurosci. Biobehav. Rev. 2014, 47:336-347.
13. Green S., Higgins J. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 2006, Wiley, Chichester, UK.
14. Higgins J., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
15. Irwin S.A., Iglewicz A., Nelesen R.A., Lo J.Y., Carr C.H., Romero S.D., Lloyd L.S. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open label proof-of-concept trial. J. Palliat. Med. 2013, 16:958-965.
16. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., Wang P.S. The eEpidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
17. Krystal J.H., Sanacora G., Duman R.S. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol. Psychiatry 2013, 73:1133-1141.
18. Lapidus K.A.B., Levitch C.F., Perez A.M., Brallier J.W., Parides M.K., Soleimani L., Feder A., Iosifescu D.V., Charney D.S., Murrough J.W. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol. Psychiatry 2014, 76:970-976.
19. Lara D.R., Bisol L.W., Munari L.R. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int. J. Neuropsychopharmacol. 2014, 16:2111-2117.
20. Manji H.K., Quiroz J.A., Sporn J., Payne J.L., Denicoff K., Gray A., Zarate N., Charney, D.S.C.A. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol. Psychiatry 2003, 53:707-742.
21. McGirr A., Berlim M.T., Bond D.J., Fleck M.P., Yatham L.N., Lam R.W. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol. Med. 2015, 45:693-704.
22. Murrough J.W., Charney D.S. Is there anything really novel on the antidepressant horizon?. Curr. Psychiatry Rep. 2012, 14:643-649.
23. Murrough J.W., Losifescu D.V., Chang L.C., Al Jurdi R.K., Green C.E., Perez A.M., Iqbal S., Pillemer S., Foulkes A., Shah A., Charney D.S., Mathew S.J. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two site randomized controlled trial. Am. J. Psychiatry 2013, 170:1134-1142.
24. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 2008, 7:426-437.
25. Skolnick P., Popik P., Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol. Sci. 2009, 30:563-569.
26. Sos P., Klirova M., Novak T., Kohutova B., Horacek J., Palenicek T. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuroendocrinol. Lett. 2013, 34:101-107.
27. Stahl S.M. Mechanism of action of ketamine. CNS Spectr. 2013, 18:171-174.
28. Taylor M.J. Could glutamate spectroscopy differentiate bipolar depression from unipolar?. J. Affect. Disord. 2014, 167:80-84.
29. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K. A randomize trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63:856-864.
30. Zarate C.A., Brutsche N.E., Ibrahim L., Franco-Chaves J., Diazgranados N., Cravchik A., Selter J., Marquardt C.A., Liberty V., Luckenbaugh D.A. Replication of Ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry 2012, 71:939-946.